- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 25, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform

KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have captured real-time images showing how a key brain enzyme organizes itself to help memory formation. Their study, published in Nature Communications, reveals that the enzyme CaMKII forms mixed α/β subunit structures whose interactions stabilize learning-related signals in neurons. A molecular switch for learning One of the brain's most important enzymes for learni

New Delhi: Experts in the pharma industry have raised their concerns over the government's move to notify a minimum import price (MIP) for certain key pharmaceutical inputs to combat aggressive undercutting and dumping from Chinese manufacturers . Experts said a chain-wide MIP on Pen-G, 6-APA and amoxicillin would raise costs across essential medicines, disrupt government tenders and concentrate supply-without clear evidence of dumping or import-led injury. "The country must protect and build it

New Delhi: Taro Pharmaceutical Industries , a unit of Sun Pharma , is recalling over 17,000 units of an antifungal medication in the US due to manufacturing issues, according to the US Food and Drug Administration ( USFDA ). According to its latest Enforcement Report, the US health regulator stated that Hawthorne-based Sun Pharma/ Taro is recalling 17,664 units of Ciclopirox Shampoo , an antifungal medication that treats seborrheic dermatitis , a condition that causes dry, flaky, and itchy skin.

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share ("Common Stock"), at a ratio of 1-for-18 (the "Reverse Stock Split"). The Reverse Stock Split is expected to

Vitamin C doesn’t just belong in skincare products—it works even better when you eat it. Scientists discovered that vitamin C from food travels through the bloodstream into every layer of the skin, boosting collagen and skin renewal. People who ate two vitamin C–packed kiwifruit daily showed thicker, healthier skin. The findings suggest glowing skin really does start from within.Scientists at the University of Otago, Faculty of Medicine -- Christchurch Ōtautahi, have identified a direct connecti

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Dec. 26, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of rat

At NSI 2025, Dr. Mohana Rao Patibandla presented India’s first 51-case series on parafascicular BrainPath surgery for intraventricular brain tumors. Intraventricular tumors demand anatomy-respecting surgery. Parafascicular access prioritizes functional preservation while enabling safe tumor removal, offering early Indian clinical evidence” — Dr. Mohana Rao Patibandla at NSI 2025. GUNTUR, ANDHRA PRADESH, INDIA, December 26, 2025 / EINPresswire.com / -- A landmark academic presentation delivered a

Alfa Cytology combines radiolabelling and radiosynthesis services with biodistribution analysis to support preclinical radiopharmaceutical research. NEW YORK, NY, UNITED STATES, December 25, 2025 / EINPresswire.com / -- As the application of radiodiagnostic and therapeutic drugs in tumor research continues to expand, researchers are placing higher demands on quality control and in vivo behavior assessment of radioactive compounds. In radiopharmaceutical research and development, completing radio

RIYADH, SAUDI ARABIA, December 25, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has successfully implemented a preventive therapy that slows the progression of Type 1 Diabetes in adults and children aged eight years and older who have been diagnosed at stage two of the disease. The therapy was first administered to two eligible patients who met the approved protocol’s criteria, marking a major step toward earlier preventive intervention in a condition